pembrolizumab,toripalimab,nivolumab,ipilimumab,Atezolizumab,durvalumab,Cisplatin,Gemcitabine,Pemetrexed,Vinorelbine,Docetaxel,Carboplatin,Paclitaxel
merck,Roche,BMS,Coherus,Junshi Biosciences,Astrazeneca
['nsclc', 'sclc']
neo vs adjuvnat io for nsclc. cross trial comparisons. may favor neo adjuvant approach . #asco23 
Oncology care , to give or not to give chemo , data analysis , oncology pharamocovigilance , enthusiastic critic, twitts are not twists